University of Oulu

NEUROPA - Non-invasive dynamic neural control by laser-based technology (863214)

Saved in:
Description:
Europe faces an enormous human toll of brain disorders, with an estimated 83 million people affected, and economic costs amounting to approximately €800 billion. Drug treatments for brain disorders prove often less than effective with a lack of selective cell targeting. A failure to develop new drugs has led major Pharmaceutical companies to withdraw from CNS drug development in recent years. Methods such as Transcranial Magnetic Stimulation or Deep Brain Stimulation have displayed some therapeutic efficacy, however they are non-selective and/or invasive. It is therefore clear that with a failure of conventional therapy, a new approach is necessary, and development of new technology. NEUROPA will directly tackle this issue. An ideal treatment would be one where activity in specific implicated neuronal networks could be selectively modulated. To be relevant to human disorders the therapy should enable the long-term modulation of dysfunctional networks. For potential widespread use in patients the intervention and monitoring of effects on network activity should also be non-invasive. NEUROPA will develop a new Phytoptogenetics technology: novel Phytochromes that will enable modulation of expression of specific genes, selectively and non-invasively delivered and targeted to cortical neurons in specific cortico-subcortical loops. Novel compact laser sources and a Diffusing Wave Spectroscopy monitoring system will be developed to enable non-invasive bidirectional control of the phytochromes by two-photon excitation. NEUROPA will achieve in-lab technology validation of long-term network activity modulation and behavioural symptom alleviation in Huntington’s and Alzheimer’s disease mouse models. To achieve this, we have assembled a consortium of phytochrome engineering, gene delivery, laser photonics and detection experts, cellular, in vivo and behavioural neuroscientists, together with drug discovery expertise. We envisage progress to human use within 15 years.
see all

Subjects:
Grant Number: 863214
Cordis Record Number: 225326
Project Start Date: 2020-01-01
Project End Date: 2022-12-31
Project Funder: EC/H2020/RIA/
EC Special Clause: false
Datapilot: true
Open Access Mandate: true
Coordinator: ASTON UNIVERSITY
Coordinator EU Contribution: 1021769.5
EU Max Contribution: 3604780
Total Cost: 3604780
Participant: OULUN YLIOPISTO
DLM CONSULTANCY SERVICES LTD
UNIVERSITAT DE BARCELONA
UNIVERSITAT BAYREUTH
PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT
SORBONNE UNIVERSITE
More information: Detailed project information (CORDIS)
Detailed project information (Openaire)
Copyright information: © European Union, 1994-2017 CORDIS, http://cordis.europa.eu/
All materials created by the OpenAIRE consortium are licensed under a Creative Commons Attribution 4.0 International License
  http://cordis.europa.eu/
https://creativecommons.org/licenses/by/4.0/